- Pfizer Inc. (NYSE: PFE) today held its Annual Meeting of Shareholders. Preliminary results from the Annual Meeting indicate that the shareholders: reelected the company's 12 director nominees to one-year terms; ratified the selection of KPMG LLP as Pfizer's independent registered public accounting firm for the 2026 fiscal year; approved the Pfizer 2019 Stock Plan, as amended April 2026; and approved, on an advisory basis, the compensation of the company's named executive officers.
In other voting, shareholders did not approve the shareholder proposal.
"We thank all shareholders for their participation today and for their ongoing support. 2025 was a year in which we delivered on our financial commitments and executed with discipline across our enterprise. I'm confident that Pfizer is in a strong position as we strive for industry-leading growth by the end of the decade, continue to deliver for patients and create sustained shareholder value," stated Albert Bourla, Pfizer Chairman and Chief Executive Officer.
The final results are subject to verification by the independent inspectors of election. The final results will be reported on a Current Report on Form 8-K to be filed by Pfizer with the U.S. Securities and Exchange Commission in the next few days.
